Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tubeimoside is a triterpenoid saponin extracted from the tuber of *Bolbostemma paniculatum* (Maxim.) Franquet, a traditional Chinese medicinal herb known as Tu Bei Mu. It possesses diverse pharmacological properties, including anti-tumor, anti-inflammatory, and anti-viral activities. In clinical development, specifically led by the Shaanxi Provincial Hospital of Traditional Chinese Medicine, tubeimoside is being investigated for the treatment of verruca plana (flat warts). The therapeutic approach involves the external application of a tubeimoside injection formulation, likely targeting the underlying viral infection and associated skin cell proliferation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tubeimoside.